Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MT-CO2 | P00403 | 6/20 | 0.45 |
| ▸ | CXCR3 | P49682 | 4/20 | 0.44 |
| ▸ | TOP1 | P11387 | 2/20 | 0.42 |
| ▸ | GPR52 | Q9Y2T5 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | KLK1 | P06870 | 1/20 | 0.40 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577674 | 0.89 | LMNA (0.44) | GPR52KMT2AP2RX7CHRM3LMNA | |
| SCHEMBL5577302 | 0.87 | MT-CO2 (0.48) | MT-CO2TOP1KMT2ACHRM3LMNA | |
| SCHEMBL5577435 | 0.87 | MT-CO2 (0.49) | MT-CO2TOP1GPR52KMT2AKLKB1 | |
| SCHEMBL5577919 | 0.86 | MT-CO2 (0.52) | MT-CO2TOP1KMT2AATMPRKAA2 | |
| SCHEMBL5577690 | 0.84 | CXCR3 (0.58) | CXCR3KMT2AKLKB1KLK1CCR1 | |
| SCHEMBL5577376 | 0.84 | MAPK8 (0.43) | MT-CO2CXCR3KMT2AP2RX7CCR1 | |
| SCHEMBL5577608 | 0.84 | MT-CO2 (0.45) | MT-CO2CXCR3TOP1GPR52KMT2A | |
| SCHEMBL5577406 | 0.84 | MT-CO2 (0.47) | MT-CO2TOP1KLKB1KLK1PRKAA2 | |
| SCHEMBL5577582 | 0.83 | MT-CO2 (0.47) | MT-CO2TOP1KMT2APRKAA2CHRM3 | |
| SCHEMBL5577671 | 0.82 | MT-CO2 (0.43) | MT-CO2CXCR3TOP1KMT2APRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | MT-CO2 2047/4885CXCR3 32/4885TOP1 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.